Replies are closed for this discussion.
Glaxo has filed for the Exon 51 skipping trial to be modified. The documentation with EMA is talking about the Exon 51 skipping trial to be split in different age groups (5->9->18) . The trail is expected to last till 2017.
Application was filed in April and a approval decision was received on July 30th. More details in the links
Who so ever has an opportunity to ask questions to GSX/PRO should be asking for clarification on how is the decision to stop the the current trail related to this new trail the GSX seeks approval from EMA.